- Company
- Law firms hire drug industry personnel to expand clients
- by Eo, Yun-Ho Oct 14, 2020 06:23am
- Law firms in South Korea are busy scouting pharmaceutical industry specialists to attract pharmaceutical company clients. The related industry sources reported law firms like Kim & Chang, Lee & Ko, Yulchon and Shin & Kim have recruited external experts for their healthcare teams for the last month. Shin & Kim has welcomed a former di
- Policy
- What is the result of 759 illegal rebate-related drugs?
- by Lee, Jeong-Hwan Oct 14, 2020 06:23am
- In the last five years, 759 drugs were counted as having received administrative disposition for illegal rebates. Dong-A ST ranked first in the number of rebate disposals with 267 items, while CJ Healthcare ranked second with 114 items and Hanall Biopharma ranked third with 74 items. Among them, only 96 items were suspended from application of m
- Policy
- Orphan drugs introduced in Korea are 'increasing'
- by Lee, Tak-Sun Oct 14, 2020 06:22am
- As the orphan drug market has recently emerged as Blue Ocean, the introduction of Orphan Drugs by global pharmaceutical companies is increasing in Korea. In particular, as the MFDS has given a PMS of up to 11 years to Orphan Drugs through amendment of regulations, the market monopoly is expected to be prolonged. According to the MFDS o
- Policy
- Copayment unchanged for using reimbursed Dupixent
- by Lee, Hye-Kyung Oct 14, 2020 06:22am
- When processing atopic dermatitis patients visiting tertiary hospitals, the healthcare institutes should now be aware that the 100-percent outpatient copayment rate does not apply to the severe case patients. On Oct. 7, the Ministry of Health and Welfare (MOHW) and Health Insurance Review and Assessment Service (HIRA) provided informatio
- Policy
- 'Adding CSO' to the target of rebate penalty
- by Lee, Jeong-Hwan Oct 13, 2020 06:05am
- A revision of the law is being promoted so that not only pharmaceutical companies that gave rebates to doctors and pharmacists, but also the Contract Sales Organization (CSO) that they delivered on their behalf, can be directly punished for violating the Pharmaceutical Affairs Law. It is to clarify the grounds for administrative dispositio
- Policy
- HIRA finally revises PE guideline after 9 years
- by Lee, Hye-Kyung Oct 13, 2020 06:05am
- Finally, the pharmacoeconomic evaluation (PE) guideline is to be revised after nine years. South Korea’s Health Insurance Review and Assessment Service (HIRA) is accepting public opinion until Dec. 6 for the unveiled draft of revised PE guideline that reflects most of the suggestions made in the 2019 research on PE guideline revision (P
- Policy
- Many companies apply for a patent challenge for Otezla
- by Lee, Tak-Sun Oct 13, 2020 06:05am
- Korean pharmaceutical companies' patent challenges are continuing on new psoriasis treatments that are not released in Korea due to the failure to apply insurance benefits. Otezla (Apremilast), which was approved in 2017 as a treatment for psoriasis and psoriatic arthritis in Korea, has recently received a patent challenge from domestic co
- Policy
- Drugs exempt from economic evaluation are applied to RSA
- by Kim, Jung-Ju Oct 13, 2020 06:05am
- From today (8th), generic drugs under risk-sharing agreements (RSA), drugs exempt from economic evaluation, and drugs released with early permission under the condition of Phase III are also covered by RSA between insurers and pharmaceutical companies. A new legal basis for adjusting the limit upper price will be established in the case o
- Company
- Daewoong's subsidiaries are all expected to turn profits
- by Oct 12, 2020 06:16am
- Daewoong's eight overseas subsidiaries are expected to make a profit this year. In the first half of this year, seven have already made a surplus. It has been about 10 years since the global organization has been in full swing. Daewoong has been the most actively seeking overseas expansion among domestic pharmaceutical companies. Starting wit
- Opinion
- [Reporter’sView] Revisiting gene list for NGS panel testing
- by Eo, Yun-Ho Oct 12, 2020 06:16am
- Human epidermal growth factor receptor 2 (HER2), anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) would be familiar terms for the people who have been paying a close attention to those news articles regarding anticancer treatment. Depending on the genetic mutation a patient has, effective treatment varies whil
